Foundation inks cancer genomics pact with AstraZeneca; MethylGene raises $26M; Merck offers interim results on melanoma drug;

Conversations on Twitter :

 @FierceBiotech: From Icon launches new functional service model. More | Follow @FierceBiotech

 @JohnCFierce: How about that--AstraZeneca gets pos. data in late-stage constipation study. Partnered with Nektar ('09 1.5B deal). More | Follow @JohnCFierce

 @RyanMFierce: Boehringer Ingelheim takes hepC message online. News | Follow @RyanMFierce

> Cambridge, MA-based Foundation Medicine has inked its ninth industry collaboration on cancer genomics, and it's another marquee player. AstraZeneca ($AZN) will put Foundation Medicine's technology to use in search of discovering genomic alterations that could help direct its R&D efforts. Foundation-a 2012 Fierce 15 company-gains first rights to negotiate on new diagnostics. "This collaboration with Foundation Medicine will help us to identify tumour-specific defects and alterations that can be used for patient segmentation," said AstraZeneca's Susan Galbraith. Release

> MethylGene has raised $26.1 million in a private placement. Release

> Merck ($MRK) says that interim results from a mid-stage study of MK-3475 in advanced melanoma revealed a 41% partial response rate among patients. No complete responses were found. Release

> Aeterna Zentaris has launched the Phase II portion of its ongoing Phase I/II study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108. Release

Pharma News

@FiercePharma: In $491mn Rapamune settlement, Pfizer to plead guilty to a misdemeanor. News | Follow @FiercePharma

> Pfizer racks up $600M-plus in Wyeth-related legal settlements. Report

> Sistema aims to buy Russia's Veropharm in potential $636M deal. Article

> Pfizer under fire in U.K. for paying little-to-no corporate tax. Story

Medical Device News

 @FierceMedDev: EarlySense in Israel raised $15M for hospital beds with sensors built in--via Globes. More | Follow @FierceMedDev

 @MarkHFierce: HeartWare boosted revenue in Q3 2012, thanks to expanded Int'l approval for its HVAD device. But net losses soared. More | Follow @MarkHFierce

 @DamianFierce: Covance took a 7% profit hit in Q3 but still topped Wall Street estimates. More | Follow @DamianFierce

> Qualcomm extends its medical device network to Europe. Report

> EarlySense pulls in $15M to boost patient monitoring tech sales. Story

> Sorin Group acquires Belgian neurostim device maker. News

Biotech IT News

> GNS turns to Big Data to crack multiple myeloma. News

> FDA updates IT after GAO lashing. Item

> Boehringer Ingelheim takes hep C message online. Article

> Private equity interest in Merge prompts breakup speculation. Story

> Maverix enters genomics software game with Silicon Valley sizzle. Report

CRO News

> Parexel looks to the future with university partnership. Item

> Covance posts profit drop but beats predictions in Q3. Story

> DiscoveRx snags BioSeek for drug development. News

> CRA buys Radiant Research to increase trial capacity. Article

> AMRI narrows losses on strong Q3. News

And Finally… Investigators say that combining PI3-kinase and PARP inhibitors may be the best approach for treating triple-negative breast cancer. Release


Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.